Kelley JA - Search Results

1

Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates.

Blaney SM, Balis FM, Hegedus L, Heideman RL, McCully C, Murphy RF, Kelley JA, Poplack DG. Blaney SM, et al. Among authors: kelley ja. Cancer Res. 1990 Dec 15;50(24):7915-9. Cancer Res. 1990. PMID: 2253232

2

A pediatric phase I and pharmacokinetic study of spirohydantoin mustard.

Heideman RL, Kelley JA, Packer RJ, Reaman GH, Roth JS, Balis F, Ettinger LJ, Doherty KM, Jeffries SL, Poplack DG. Heideman RL, et al. Among authors: kelley ja. Cancer Res. 1988 Apr 15;48(8):2292-5. Cancer Res. 1988. PMID: 3349492

3

Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics.

Zaharko DS, Kelley JA, Tomaszewski JE, Hegedus L, Hartman NR. Zaharko DS, et al. Among authors: kelley ja. Invest New Drugs. 1991 Feb;9(1):9-17. doi: 10.1007/BF00194539. Invest New Drugs. 1991. PMID: 2026489

4

The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.

Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, Nadkarni M, Balis FM, Broder S, Johns DG. Kelley JA, et al. Drug Metab Dispos. 1987 Sep-Oct;15(5):595-601. Drug Metab Dispos. 1987. PMID: 2891473

5

Reversed-phase high-performance liquid chromatographic determination of the new antitumor agent cyclopentenyl cytosine in biological fluids.

Hegedus L, Ford H Jr, Hartman NR, Kelley JA. Hegedus L, et al. Among authors: kelley ja. J Chromatogr B Biomed Sci Appl. 1997 Apr 25;692(1):169-79. doi: 10.1016/s0378-4347(96)00464-1. J Chromatogr B Biomed Sci Appl. 1997. PMID: 9187397

6

2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition.

Roth JS, McCully CM, Balis FM, Poplack DG, Kelley JA. Roth JS, et al. Among authors: kelley ja. Drug Metab Dispos. 1999 Oct;27(10):1128-32. Drug Metab Dispos. 1999. PMID: 10497138

7

Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid.

Collins JM, Klecker RW Jr, Kelley JA, Roth JS, McCully CL, Balis FM, Poplack DG. Collins JM, et al. Among authors: kelley ja. J Pharmacol Exp Ther. 1988 May;245(2):466-70. J Pharmacol Exp Ther. 1988. PMID: 3367302

8

Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.

Ward FT, Kelley JA, Roth JS, Lombardo FA, Weiss RB, Leyland-Jones B, Chun HG. Ward FT, et al. Among authors: kelley ja. Cancer Res. 1991 Apr 1;51(7):1803-10. Cancer Res. 1991. PMID: 2004365 Clinical Trial.

9

In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors.

Viola JJ, Agbaria R, Walbridge S, Oshiro EM, Johns DG, Kelley JA, Oldfield EH, Ram Z. Viola JJ, et al. Among authors: kelley ja. Cancer Res. 1995 Mar 15;55(6):1306-9. Cancer Res. 1995. PMID: 7882327

10

Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Politi PM, Xie F, Dahut W, Ford H Jr, Kelley JA, Bastian A, Setser A, Allegra CJ, Chen AP, Hamilton JM, et al. Politi PM, et al. Among authors: kelley ja. Cancer Chemother Pharmacol. 1995;36(6):513-23. doi: 10.1007/BF00685802. Cancer Chemother Pharmacol. 1995. PMID: 7554044 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters